A Phase 1 Single- and Multiple-ascending-dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of S-740792 in Healthy Adult Study Participants
Latest Information Update: 17 Dec 2024
Price :
$35 *
At a glance
- Drugs S 740792 (Primary) ; Midazolam
- Indications Neurologic gait disorders
- Focus Adverse reactions
- Sponsors Shionogi
- 17 Dec 2024 New trial record